As Sarepta And Valeant Exit Hearings, Biotech Steps Into M&A

The last week was a nonstop whirlwind for biotech, so I’ve decided to treat this entry a little differently by commenting on key events and share what I’ve been seeing. Valeant’s outgoing CEO J. Michael Pearson, from left; former chief financial officer Howard Schiller and billionaire investor William Ackman, whose hedge […]

Original: Forbes Real Time